Enterococcus faecalis gelatinase mediates intestinal permeability via protease-activated receptor 2

Infection and Immunity

Volumn 83, Issue 7, 2015, Pages 2762-2770

  Maharshak, Nitsan ^a   Huh, Eun Young ^b   Paiboonrungruang, Chorlada ^b   Shanahan, Michael ^b   Thurlow, Lance ^b   Herzog, Jeremy ^b   Djukic, Zorka ^b   Orlando, Roy ^b   Pawlinski, Rafal ^b   Ellermann, Melissa ^b   Borst, Luke ^c   Patel, Siten ^b   Dotan, Iris ^a   Sartor, Ryan B ^b   Carroll, Ian M ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; DEXTRAN; ENTEROCOCCUS FAECALIS GELATINASE; FLUORESCEIN ISOTHIOCYANATE; GELATINASE; PROTEINASE ACTIVATED RECEPTOR 2; UNCLASSIFIED DRUG; CONDITIONED MEDIUM;

ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CACO 2 CELL LINE; COLON MUCOSA; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; EPITHELIUM; EPITHELIUM CELL; GENE; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPERNATANT; ULCERATIVE COLITIS; WILD TYPE; ANIMAL; C57BL MOUSE; CELL LINE; COLON; CONDITIONED MEDIUM; DEFICIENCY; ENZYMOLOGY; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; PERMEABILITY; PHYSIOLOGY;

ANIMALS; CELL LINE; COLON; CULTURE MEDIA, CONDITIONED; ENTEROCOCCUS FAECALIS; EPITHELIAL CELLS; GELATINASES; HUMANS; INTESTINAL MUCOSA; MICE, INBRED C57BL; MICE, KNOCKOUT; PERMEABILITY; RECEPTOR, PAR-2;

EID: 84930986570     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00425-15     Document Type: Article

References (59)

1. Arnott ID, Kingstone K, Ghosh S. 2000. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 35:1163-1169. http://dx.doi.org/10.1080/003655200750056637.
2. D'Incà R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC. 1999. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 94: 2956-2960. http://dx.doi.org/10.1111/j.1572-0241.1999.01444.x.
3. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. 2006. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 101: 1288-1294. http://dx.doi.org/10.1111/j.1572-0241.2006.00672.x.
4. Lee JW, Park JH, Park DI, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI. 2010. Subjects with diarrhea-predominant IBS have increased rectal permeability responsive to tryptase. Dig Dis Sci 55:2922-2928. http://dx.doi.org/10.1007/s10620-009-1094-8.
5. McOmber ME, Ou CN, Shulman RJ. 2010. Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults. J Pediatr Gastroenterol Nutr 50:269-275. http://dx.doi.org/10 .1097/MPG.0b013e3181aa3aa9.
6. Meddings JB, Sutherland LR, May GR. 1994. Intestinal permeability in patients with Crohn's disease. Gut 35:1675-1676.
7. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. 1993. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 341: 1437-1439. http://dx.doi.org/10.1016/0140-6736(93)90882-H.
8. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI. 1986. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105:883-885.
9. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, Krugliak P, Rotter JI. 1989. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97:927-931.
10. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz KD, Binder V. 1994. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 35:68-72. http://dx.doi.org/10.1136/gut.35.1.68.
11. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. 1996. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076-2085. http://dx.doi.org /10.1172/JCI119013.
12. Dubeau MF, Iacucci M, Beck PL, Moran GW, Kaplan GG, Ghosh S, Panaccione R. 2013. Drug-induced inflammatory bowel disease and IBDlike conditions. Inflamm Bowel Dis 19:445-456. http://dx.doi.org/10 .1002/ibd.22990.
13. Neurath H. 1984. Evolution of proteolytic enzymes. Science 224:350-357. http://dx.doi.org/10.1126/science.6369538.
14. Biancheri P, Di Sabatino A, Corazza GR, MacDonald TT. 2013. Proteases and the gut barrier. Cell Tissue Res 351:269-280. http://dx.doi.org /10.1007/s00441-012-1390-z.
15. Ishihara H, Connolly AJ, Zeng D, Kahn ML, Zheng YW, Timmons C, Tram T, Coughlin SR. 1997. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502-506. http://dx.doi.org/10 .1038/386502a0.
16. Kahn ML, Hammes SR, Botka C, Coughlin SR. 1998. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem 273:23290-23296. http://dx.doi.org/10.1074 /jbc.273.36.23290.
17. Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J. 1995. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem 232:84-89. http: //dx.doi.org/10.1111/j.1432-1033.1995.tb20784.x.
18. Vu TK, Hung DT, Wheaton VI, Coughlin SR. 1991. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068. http://dx.doi.org/10.1016/0092 -8674(91)90261-V.
19. Xu WF, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. 1998. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 95:6642-6646. http://dx.doi.org/10.1073/pnas.95.12.6642.
20. Hollenberg MD, Compton SJ. 2002. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54:203-217.
21. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL, Morelli A, Cirino G. 2001. Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A 98:13936-13941. http://dx.doi.org/10.1073/pnas.241377298.
22. Cenac N, Cellars L, Steinhoff M, Andrade-Gordon P, Hollenberg MD, Wallace JL, Fiorucci S, Vergnolle N. 2005. Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis 11:792-798. http://dx.doi.org/10 .1097/01.mib.0000177506.71784.bd.
23. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, Mac-Naughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N. 2002. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2.AmJ Pathol 161:1903-1915. http://dx.doi.org/10.1016/S0002-9440(10)64466-5.
24. Dabek M, Ferrier L, Annahazi A, Bezirard V, Polizzi A, Cartier C, Leveque M, Roka R, Wittmann T, Theodorou V, Bueno L. 2011. Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: role of cathepsin G and protease-activated receptor-4. Inflamm Bowel Dis 17:1409-1414. http://dx.doi.org/10.1002/ibd.21454.
25. Vergnolle N. 2005. Clinical relevance of proteinase activated receptors (PARs) in the gut. Gut 54:867-874. http://dx.doi.org/10.1136/gut.2004 .048876.
26. Pruteanu M, Hyland NP, Clarke DJ, Kiely B, Shanahan F. 2011. Degradation of the extracellular matrix components by bacterial-derived metalloproteases: implications for inflammatory bowel diseases. Inflamm Bowel Dis 17:1189-1200. http://dx.doi.org/10.1002/ibd.21475.
27. Steck N, Hoffmann M, Sava IG, Kim SC, Hahne H, Tonkonogy SL, Mair K, Krueger D, Pruteanu M, Shanahan F, Vogelmann R, Schemann M, Kuster B, Sartor RB, Haller D. 2011. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology 141:959-971. http://dx.doi.org/10.1053/j .gastro.2011.05.035.
28. Kim SC, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, Braun J, Huycke MM, Sartor RB. 2005. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128:891-906. http://dx.doi.org/10 .1053/j.gastro.2005.02.009.
29. Thomas VC, Thurlow LR, Boyle D, Hancock LE. 2008. Regulation of autolysis-dependent extracellular DNA release by Enterococcus faecalis extracellular proteases influences biofilm development. J Bacteriol 190: 5690-5698. http://dx.doi.org/10.1128/JB.00314-08.
30. Aakra A, Vebo H, Snipen L, Hirt H, Aastveit A, Kapur V, Dunny G, Murray BE, Nes IF. 2005. Transcriptional response of Enterococcus faecalis V583 to erythromycin. Antimicrob Agents Chemother 49:2246-2259. http://dx.doi.org/10.1128/AAC.49.6.2246-2259.2005.
31. Shankar J, Walker RG, Ward D, Horsburgh MJ. 2012. The Enterococcus faecalis exoproteome: identification and temporal regulation by Fsr. PLoS One 7:e33450. http://dx.doi.org/10.1371/journal.pone.0033450.
32. Rao R, Baker RD, Baker SS. 1999. Inhibition of oxidant-induced barrier disruption and protein tyrosine phosphorylation in Caco-2 cell monolayers by epidermal growth factor. Biochem Pharmacol 57:685-695. http: //dx.doi.org/10.1016/S0006-2952(98)00333-5.
33. Chin AC, Lee WY, Nusrat A, Vergnolle N, Parkos CA. 2008. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration. J Immunol 181:5702-5710. http://dx.doi.org/10.4049/jimmunol.181.8.5702.
34. Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC. 2013. Defective barrier function in neosquamous epithelium. Am J Gastroenterol 108:386-391. http://dx.doi.org/10.1038/ajg.2012.440.
35. Róka R, Rosztoczy A, Leveque M, Izbeki F, Nagy F, Molnar T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, Bueno L. 2007. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 5:550-555. http://dx.doi.org/10.1016/j.cgh.2006.12.004.
36. Hancock LE, Perego M. 2004. The Enterococcus faecalis fsr twocomponent system controls biofilm development through production of gelatinase. J Bacteriol 186:5629-5639. http://dx.doi.org/10.1128/JB.186 .17.5629-5639.2004.
37. Wiśniewski JR, Zougman A, Nagaraj N, Mann M. 2009. Universal sample preparation method for proteome analysis. Nat Methods 6:359-362. http://dx.doi.org/10.1038/nmeth.1322.
38. Turowec JP, Zukowski SA, Knight JD, Smalley DM, Graves LM, Johnson GL, Li SS, Lajoie GA, Litchfield DW. 2014. An unbiased proteomic screen reveals caspase cleavage is positively and negatively regulated by substrate phosphorylation. Mol Cell Proteomics 13:1184-1197. http://dx .doi.org/10.1074/mcp.M113.037374.
39. Cleynen I, Vazeille E, Artieda M, Verspaget HW, Szczypiorska M, Bringer MA, Lakatos PL, Seibold F, Parnell K, Weersma RK, Mahachie John JM, Morgan-Walsh R, Staelens D, Arijs I, De Hertogh G, Muller S, Tordai A, Hommes DW, Ahmad T, Wijmenga C, Pender S, Rutgeerts P, Van Steen K, Lottaz D, Vermeire S, Darfeuille-Michaud A. 2014. Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease. Gut 63:1265-1274. http://dx.doi.org /10.1136/gutjnl-2012-303205.
40. Kawalec M, Potempa J, Moon JL, Travis J, Murray BE. 2005. Molecular diversity of a putative virulence factor: purification and characterization of isoforms of an extracellular serine glutamyl endopeptidase of Enterococcus faecalis with different enzymatic activities. J Bacteriol 187:266-275. http://dx.doi.org/10.1128/JB.187.1.266-275.2005.
41. Paulsen IT, Banerjei L, Myers GS, Nelson KE, Seshadri R, Read TD, Fouts DE, Eisen JA, Gill SR, Heidelberg JF, Tettelin H, Dodson RJ, Umayam L, Brinkac L, Beanan M, Daugherty S, DeBoy RT, Durkin S, Kolonay J, Madupu R, Nelson W, Vamathevan J, Tran B, Upton J, Hansen T, Shetty J, Khouri H, Utterback T, Radune D, Ketchum KA, Dougherty BA, Fraser CM. 2003. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science 299:2071-2074. http: //dx.doi.org/10.1126/science.1080613.
42. Chen Y, Yang C, Wang ZJ. 2011. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxelinduced neuropathic pain. Neuroscience 193:440-451. http://dx.doi.org /10.1016/j.neuroscience.2011.06.085.
43. Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD. 2011. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 130:248-282. http://dx.doi .org/10.1016/j.pharmthera.2011.01.003.
44. Fish SM, Proujansky R, Reenstra WW. 1999. Synergistic effects of interferon gamma and tumour necrosis factor alpha on T84 cell function. Gut 45:191-198. http://dx.doi.org/10.1136/gut.45.2.191.
45. Patrick DM, Leone AK, Shellenberger JJ, Dudowicz KA, King JM. 2006. Proinflammatory cytokines tumor necrosis factor-alpha and interferongamma modulate epithelial barrier function in Madin-Darby canine kidney cells through mitogen activated protein kinase signaling.BMCPhysiol 6:2. http://dx.doi.org/10.1186/1472-6793-6-2.
46. Carroll IM, Ringel-Kulka T, Ferrier L, Wu MC, Siddle JP, Bueno L, Ringel Y. 2013. Fecal protease activity is associated with compositional alterations in the intestinal microbiota. PLoS One 8:e78017. http://dx.doi .org/10.1371/journal.pone.0078017.
47. Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS. 2010. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 16: 2034-2042. http://dx.doi.org/10.1002/ibd.21319.
48. Fite A, Macfarlane S, Furrie E, Bahrami B, Cummings JH, Steinke DT, Macfarlane GT. 2013. Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol 51:849-856. http://dx.doi.org/10.1128/JCM .02574-12.
49. Carroll IM, Maharshak N. 2013. Enteric bacterial proteases in inflammatory bowel disease-pathophysiology and clinical implications. World J Gastroenterol 19:7531-7543. http://dx.doi.org/10.3748/wjg.v19.i43.7531.
50. Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, Yeom JJ, Kim TH, Nah YH, Lee YM. 2003. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 9:224-229. http://dx.doi.org/10 .1097/00054725-200307000-00002.
51. Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S. 2004. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 114:1444-1456. http: //dx.doi.org/10.1172/JCI21689.
52. Annaházi A, Gecse K, Dabek M, Ait-Belgnaoui A, Rosztoczy A, Roka R, Molnar T, Theodorou V, Wittmann T, Bueno L, Eutamene H. 2009. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 144:209-217. http://dx .doi.org/10.1016/j.pain.2009.04.017.
53. Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, Fairlie DP. 2012. An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J 26:2877-2887. http://dx.doi .org/10.1096/fj.11-201004.
54. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. 1994. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci U S A 91:9208-9212. http://dx.doi.org/10.1073/pnas.91.20.9208.
55. Molino M, Woolkalis MJ, Reavey-Cantwell J, Pratico D, Andrade-Gordon P, Barnathan ES, Brass LF. 1997. Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J Biol Chem 272:11133-11141.
56. Déry O, Corvera CU, Steinhoff M, Bunnett NW. 1998. Proteinaseactivated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 274:C1429-C1452.
57. Giacaman RA, Asrani AC, Ross KF, Herzberg MC. 2009. Cleavage of protease-activated receptors on an immortalized oral epithelial cell line by Porphyromonas gingivalis gingipains. Microbiology 155:3238-3246. http: //dx.doi.org/10.1099/mic.0.029132-0.
58. Thurlow LR, Thomas VC, Narayanan S, Olson S, Fleming SD, Hancock LE. 2010. Gelatinase contributes to the pathogenesis of endocarditis caused by Enterococcus faecalis. Infect Immun 78:4936-4943. http://dx .doi.org/10.1128/IAI.01118-09.
59. Thomas VC, Hiromasa Y, Harms N, Thurlow L, Tomich J, Hancock LE. 2009. A fratricidal mechanism is responsible for eDNA release and contributes to biofilm development of Enterococcus faecalis. Mol Microbiol 72:1022-1036. http://dx.doi.org/10.1111/j.1365-2958.2009.06703.x.